Structures by: Pu Y. Q.
Total: 15
Methyl 3-(dimethylamino)-2-(2-{1-[3-(2-methylphenyl)-1,2,4-oxadiazol -5-yl]-2-(dimethylamino)vinyloxyl}phenyl)acrylate
C25H28N4O4
Acta Crystallographica Section E (2005) 61, 5 o1426-o1428
a=10.250(2)Å b=10.691(2)Å c=12.263(3)Å
α=105.46(3)° β=110.74(3)° γ=92.30(3)°
4-{[3-(2-Chlorophenyl)-1,2,4-oxadiazol-5-yl]methyl}-1-[(2,6- dimethylphenyl)aminocarbonylmethyl]piperazine
C23H26ClN5O2
Acta Crystallographica Section E (2005) 61, 7 o1994-o1996
a=12.2960(10)Å b=10.587(2)Å c=17.164(2)Å
α=90.00° β=99.77(3)° γ=90.00°
1-[(2,6-Dimethylphenyl)aminocarbonylmethyl]- 4-{[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]methyl}piperazine
C23H26N6O4
Acta Crystallographica Section E (2004) 60, 11 o2041-o2042
a=7.2240(14)Å b=9.5650(19)Å c=33.245(7)Å
α=90.00° β=95.22(3)° γ=90.00°
Methyl 2-{[3-(2-methyl)phenyl-1,2,4-oxadiazol-5-yl]methoxy}phenylacetate
C19H18N2O4
Acta Crystallographica Section E (2005) 61, 5 o1390-o1392
a=11.444(2)Å b=7.9540(16)Å c=19.356(4)Å
α=90.00° β=102.83(3)° γ=90.00°
3-[3-(Methoxyl)phenyl]-5-chloromethyl-1,2,4-oxadiazole
C10H9ClN2O2
Acta Crystallographica Section E (2005) 61, 5 o1446-o1447
a=7.2350(14)Å b=9.5600(19)Å c=15.454(3)Å
α=90.00° β=97.03(3)° γ=90.00°
Methyl 2-[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-ylmethoxy]phenylacetate
C18H15ClN2O4
Acta Crystallographica Section E (2005) 61, 6 o1858-o1860
a=11.314(2)Å b=7.9510(16)Å c=19.598(4)Å
α=90.00° β=103.08(3)° γ=90.00°
Methyl 2-(2-{1-[3-(2-chlorophenyl)-1,2,4-oxadiazol-5-yl]-2- (dimethylamino)vinyloxy}phenyl)-3-(dimethylamino)acrylate
C24H25ClN4O4
Acta Crystallographica Section E (2005) 61, 11 o3879-o3880
a=16.088(3)Å b=8.3060(17)Å c=17.358(4)Å
α=90.00° β=95.79(3)° γ=90.00°
1-[(2,6-Dimethylphenyl)aminocarbonylmethyl]4-{[3-(3-methoxyphenyl)- 1,2,4-oxadiazol-5-yl]methyl}piperazine
C24H29N5O3
Acta Crystallographica Section E (2005) 61, 11 o3750-o3751
a=17.120(3)Å b=10.271(2)Å c=13.042(3)Å
α=90.00° β=91.10(3)° γ=90.00°
Methyl 2-[3-(4-bromophenyl)-1,2,4-oxadiazol-5-ylmethoxy]phenylacetate
C18H15BrN2O4
Acta Crystallographica Section E (2006) 62, 3 o1131-o1132
a=20.011(4)Å b=9.643(2)Å c=18.089(4)Å
α=90.00° β=98.33(3)° γ=90.00°
Methyl 2-{[3-(4-methylsulfanyl)phenyl-1,2,4-oxadiazol- 5-yl]methoxy}phenylacetate
C19H18N2O4S
Acta Crystallographica Section E (2004) 60, 11 o2122-o2124
a=8.3580(17)Å b=10.522(2)Å c=10.581(2)Å
α=90.13(3)° β=102.08(3)° γ=99.73(3)°
Methyl 2-(2-{1-[3-(3,5-dimethoxyphenyl)-1,2,4-oxadiazol-5-yl]-2- (dimethylamino)vinyloxy}phenyl)-3-(dimethylamino)acrylate
C26H30N4O6
Acta Crystallographica Section E (2004) 60, 11 o2070-o2072
a=8.6500(17)Å b=10.700(2)Å c=14.817(3)Å
α=107.66(3)° β=97.50(3)° γ=95.15(3)°
Methyl 2-{[3-(4-nitrophenyl)-1,2,4-oxadiazol-5-yl]methoxy}phenylacetate
C18H15N3O6
Acta Crystallographica Section E (2004) 60, 11 o2073-o2075
a=10.436(2)Å b=5.1800(10)Å c=31.560(6)Å
α=90.00° β=92.94(3)° γ=90.00°
Methyl 3-(dimethylamino)-2-[2-(1-{3-[4-(methylsulfanyl)phenyl]-1,2,4-oxadiazol-5-yl}- 2-(dimethylamino)vinyloxy)phenyl]acrylate
C25H28N4O4S
Acta Crystallographica Section E (2005) 61, 1 o58-o59
a=8.2940(17)Å b=12.654(3)Å c=23.601(5)Å
α=90.00° β=97.02(3)° γ=90.00°
Methyl 3-dimethylamino-2-(2-{2-dimethylamino-1-[3-(3-pyridyl)-1,2,4-oxadiazol- 5-yl]vinyloxy}phenyl)acrylate
C23H25N5O4
Acta Crystallographica Section E (2005) 61, 4 o1010-o1012
a=8.6250(17)Å b=9.6390(19)Å c=26.273(5)Å
α=90.00° β=91.28(3)° γ=90.00°
5-Chloromethyl-3-[4-(methylsulfonyl)phenyl]-1,2,4-oxadiazole
C10H9ClN2O3S
Acta Crystallographica Section E (2005) 61, 4 o953-o954
a=5.6170(11)Å b=12.247(2)Å c=16.993(3)Å
α=90.00° β=93.06(3)° γ=90.00°